Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Quarck, T. Nawrot, E. Ninio, B. Meyns, D. Van Raemdonck, E. Verbeken, M. Delcroix (Leuven, Belgium; Paris, France). C-reactive protein and platelet-activating factor-acetylhydrolase activity: new predictors of outcome in pulmonary hypertension. Eur Respir J 2008; 32: Suppl. 52, 1425

Member's Comments

No comment yet.

Related content which might interest you: C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Could platelet-activating factor acetylhydrolase (PAF-AH) predict adverse event in pulmonary hypertension? Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Analysis of C-reactive protein and fibrinogen as possible predictors of secondary fibrosis in pulmonary tuberculosis Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011 Platelet-activating factor-acetylhydrolase (PAF-AH) activity in pulmonary arterial hypertension (PAH) Source: Eur Respir J 2005; 26: Suppl. 49, 695s Year: 2005 The relation of serum interleukin-6 and C-reactive protein to clinical parameters in pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 35s Year: 2004 Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension Source: Eur Respir J 2014; 43: 912-914 Year: 2014 C-reactive protein levels and clinically important predictive outcomes in stable COPD patients Source: Eur Respir J 2006; 27: 902-907 Year: 2006 PP302 – The relationship between the level of C-reactive protein and the general cardiovascular risk in patients with COPD and hypertension Source: ERS Lung Science Conference 2021 Year: 2021 Vascular wall remodeling in patients with chronic thromboembolic pulmonary hypertension: a role for C-reactive protein Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 Elevated factor FVIII:C levels in patients with pulmonary hypertension: a marked of endothelial dysfunction? Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003 The importance of high plasma levels of factor VIIIc in the severity of pulmonary thromboembolism Source: Eur Respir J 2001; 18: Suppl. 33, 252s Year: 2001 C-reactive protein in pulmonary TB Source: Annual Congress 2009 - Diagnostic advances in tuberculosis Year: 2009 C-reactive protein in pulmonary tuberculosis-correlation with extent and severity of the disease Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Source: Eur Respir J 2008; 32: 1451-1457 Year: 2008 D-dimer to C-reactive protein (CRP) ratio in patients with suspected pulmonary embolism Source: Annual Congress 2010 - Pulmonary embolism Year: 2010 C-reactive protein levels in COPD according to clinical parameters, smoking behavior and pulmonary hypertension Source: Annual Congress 2012 - Cell biology, blood and sputum biomarkers in airway diseases Year: 2012 Regulation of inflammation process in chronic thromboembolic pulmonary hypertension: a potential role of platelet-activating factor-acetylhydrolase Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Thromboprophylaxis and the relationship between C-reactive protein and plasma fibrinogen in patients with acute exacerbations of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 555s Year: 2007 C-reactive protein (CRP) as a risk marker in COPD patients with ischaemic heart disease Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008 Interleukin-2 and C-reactive protein in assessing the effectiveness of pulmonary sarcoidosis treatment Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017